You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of an Orally Available Therapeutic for Neutralizing C. difficile Toxin B

    SBC: NECTAGEN INC            Topic: NIAID

    Infection with the bacterium C. difficile is the most common and increasingly prevalent cause of diarrhea. In the United States, cases of C. difficile infection (CDI) are estimated to number 500,000 annually and to result in an estimated 15,000 to 30,000 deaths. The cost of these cases is thought to exceed $4.8 billion annually. CDI continues to cause discomfort, serious illness and sometimes deat ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Real-time Multimodal Diffuse Reflectance and Polarization Imaging Based Nerve Identification in Surgical Field of View

    SBC: YAYA SCIENTIFIC LLC            Topic: NIBIB

    PROJECT SUMMARY We propose to develop a novel non-contact, label-free multimodality imager that provides real-time intraoperative identification of nerves within the surgical field-of-view to facilitate the prevention of unintended nerve damage (termed iatrogenic nerve injury) during surgical procedures, as they are a major source of postsurgical complications, e.g., chronic pain. In the United St ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. STARTUP Central

    SBC: CONTINUUM EDUCATIONAL TECHNOLOGIES, PBC            Topic: 500

    PROJECT SUMMARY Continuum Educational Technologies’ (Continuum) will work with the University of Kansas (KU) on the proposed I-RED program entitled Smart Tools to Accelerate Research Translation by Uplifting Participants for the Central IDeA State Region (STARTUP Central) program to stimulate technological innovation in the IDeA state regions by addressing the entrepreneurial educational needs o ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Optimizing Small Molecule Mechanomimetics to Treat Age-related Osteoporosis.

    SBC: OAK RIDGE THERAPEUTIC DISCOVERY LLC            Topic: NIA

    Abstract There is an unmet need to develop treatments for senile osteoporosis, a disorder characterized by an age-related reciprocal decrease in osteogenesis and increase in bone marrow fat. Senile osteoporosis resembles disuse osteopenia, suggesting its pathogenesis involves impaired bone mechanosensing. We discovered that the polycystin heterotrimeric complex (1PC1+3PC2) functions as a mechanose ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Developing a selective TRPC3 ion channel inhibitor for epilepsy treatment

    SBC: SEAK Therapeutics, LLC            Topic: 106

    Project SummaryEpilepsy is one of the most common brain disorders. Current drugs have limited efficacy. Identifying new targeted drugs that can be used as safer, more effective therapies is in urgent unmet need. Selective inhibition of the transient receptor potential canonical 3 (TRPC3) emerges as a novel strategy to impede epilepsy. However, the currently best selective TRPC3 inhibitor, Pyr3, ha ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Non-Invasive Venous Waveform Analysis (NIVA) in patients with Heart Failure (HF)

    SBC: Volumetrix, LLC            Topic: NHLBI

    Project Summary Volume overload (congestion) occurs in patients with heart failure (HF) and is the leading cause of hospitalization in the elderly worldwide. Unfortunately, clinical signs and symptoms; laboratory values; and existing diagnostic tools are unreliable in providing accurate assessment of volume status. Using a unique physiologic signal, Non-Invasive Venous waveform Analysis (NIVA), Vo ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Precision Guidance of Resuscitation and Deresuscitation in Sepsis

    SBC: DAXOR CORPORATION            Topic: 300

    ABSTRACT Sepsis impacts 1.7 million Americans annually, leading to 270,000 deaths and $62 billion in costs. Most of the sepsis treatment follows the Surviving Sepsis Campaign (SSC) guidelines, consisting of early antibiotics, liberal fluid resuscitation, and vasopressor use in persistent hypotension. However, the fundamental assumption that sepsis universally results in high capillary leak leading ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Integration of non-invasive deep tissue microwave thermometry in the VectRx hyperthermia device in a transgenic liver tumor pig model

    SBC: NeoTherma Oncology Inc.            Topic: 102

    Project Summary/Abstract NeoTherma Oncology (NTO/www.neothermaoncology.com) has developed a novel non-invasive medical device that delivers mild hyperthermia (HT) loco-regionally as adjuvant therapy to standard of care treatment of abdominal deep-seated tumors. The VectRx™ device, designated “Breakthrough” by the FDA, has demonstrated its ability to safely heat abdominal organs (pancreas, li ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a novel depot delivery system for a glaucoma therapeutic

    SBC: OCULO THERAPY LLC            Topic: NEI

    Glaucoma is the leading cause of irreversible blindness in the world. Because elevated intraocular pressure (IOP) and IOP fluctuations are the primary risk factors for loss of visual field, the current standard of care for adult-onset glaucoma includes treatment with IOP-lowering medications, which are typically delivered topically as eye drops. Unfortunately, the need for self-administration nega ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Oral Dissolvable Strips (ODS) as new pediatric and adult delivery mode of therapy for latent tuberculosis

    SBC: OAK THERAPEUTICS INC            Topic: NIAID

    PROJECT SUMMARY Tuberculosis (TB) remains one of the major sources of mortality from infectious diseases worldwide. In 2021 an estimated 6.4 million were newly diagnosed with TB globally, approximately 10.6 million fell ill from it, and 1.4 million died from the disease. Of those who died from the disease, 54% were men, 32% women, and 14% were children aged lt15 years. TB is also a leading cause o ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government